2025
Clinical Effectiveness of Transcatheter Left Atrial Appendage Occlusion With Watchman FLX Compared With First-Generation Watchman
Price M, Tan Z, Zimmerman S, Curtis J, Freeman J. Clinical Effectiveness of Transcatheter Left Atrial Appendage Occlusion With Watchman FLX Compared With First-Generation Watchman. JACC Cardiovascular Interventions 2025, 18: 1318-1326. PMID: 40436498, DOI: 10.1016/j.jcin.2025.03.025.Peer-Reviewed Original ResearchConceptsWatchman FLXNational Cardiovascular Data Registry LAAO RegistryDevice-related thrombusIschemic strokeClinical effectsWatchman 2.5Peridevice leakAppendage occlusionAdverse eventsAssociated with significantly lower riskTranscatheter left atrial appendage occlusionSignificantly lower riskLeft atrial appendage occlusionSecondary analysisPropensity score matching analysisScore matching analysisStudy cohortPropensity score matchingSystemic embolismAnatomical closureTransesophageal echocardiographyPrimary endpointLow riskProcedural complicationsWatchman deviceImpact of radiation therapy on the immunological tumor microenvironment
Guilbaud E, Naulin F, Meziani L, Deutsch E, Galluzzi L. Impact of radiation therapy on the immunological tumor microenvironment. Cell Chemical Biology 2025, 32: 678-693. PMID: 40280118, DOI: 10.1016/j.chembiol.2025.04.001.Peer-Reviewed Original ResearchConceptsImmunological tumor microenvironmentRadiation therapyTumor microenvironmentExternal beam radiation therapyImpact of radiation therapyBeam radiation therapyImpact tumor growthIrradiated cancer cellsEffects of RTModern cancer managementMalignant cellsPalliative settingImmune cellsTumor ecosystemTumor growthCancer managementTherapeutic windowClinical effectsCancer cellsNormal cellsCellular mechanismsHealthy tissueCytotoxic effectsTherapyDNA damage
2024
Mechanical clot disruption during pulmonary thromboembolectomy is safe: A propensity score-matched analysis
Thomas S, Deshmukh A, Mojibian H, Marino A, Lozada J, Cornman-Homonoff J. Mechanical clot disruption during pulmonary thromboembolectomy is safe: A propensity score-matched analysis. Clinical Imaging 2024, 118: 110381. PMID: 39637758, DOI: 10.1016/j.clinimag.2024.110381.Peer-Reviewed Original ResearchPulmonary thromboembolectomyPulmonary emboliPulmonary arteryRight pulmonary arteryLeft pulmonary arteryPulmonary artery pressureAdministration of anticoagulantsDuration of hospitalizationMechanical clot disruptionPropensity-score matchingSPESI scorePulmonary vasculatureArterial pressureClinical effectsOrganized thrombusThromboembolectomyPropensity-scoreClot disruptionInclusion criteriaPatientsMortality rateRisk categoriesCompare groupsStudy periodArteryThe early-onset Alzheimer’s disease MRI signature: a replication and extension analysis in early-stage AD
Mehta R, Keith C, Teixeira C, Worhunsky P, Phelps H, Ward M, Miller M, Navia R, Pockl S, Rajabalee N, Coleman M, D’Haese P, Rezai A, Wilhelmsen K, Haut M. The early-onset Alzheimer’s disease MRI signature: a replication and extension analysis in early-stage AD. Cerebral Cortex 2024, 34: bhae475. PMID: 39714256, PMCID: PMC11664631, DOI: 10.1093/cercor/bhae475.Peer-Reviewed Original ResearchConceptsEarly-onset Alzheimer's diseaseLate-onset Alzheimer's diseaseNon-AD pathologyCognitively normal individualsManagement of personsCortical atrophyFunctional statusEarly-stage ADRural populationAlzheimer's diseaseDisease stageLongitudinal studyCortical signatureWhole-brainCortical thinningCortical analysisClinical cohortNormal individualsClinical effectsSignature regionsIndividualsPersonsEarly disease stagesMRI signaturesClinical Effectiveness of Genetic Testing Guidelines in Patients with Thoracic Aortic Aneurysms
Erez E, Acuna Higaki A, Cupo M, Phu T, Verma S, Assi R, Vallabhajosyula P. Clinical Effectiveness of Genetic Testing Guidelines in Patients with Thoracic Aortic Aneurysms. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 39321868, DOI: 10.1016/j.jtcvs.2024.09.026.Peer-Reviewed Original ResearchFeatures of connective tissue diseaseThoracic aortic diseaseConnective tissue diseaseThoracic aortic aneurysmGenetic testing guidelinesSyndromic featuresMutation rateFamily historyVUS rateAortic aneurysmPrimary genesGenetic testingAssociated with thoracic aortic diseaseThoracic aorta diameterTesting guidelinesAorta diameterPathogen mutation rateAortic diseaseRisk stratificationSecondary genesPathogenic mutationsTissue diseaseClinical effectsVUSGenesDoes format matter? A naturalistic study of digital and provider-led cognitive behavioral therapy for insomnia implemented in a healthcare system
Reed A, Rogers D, Berlin G, Burrone L, Dante G, DeViva J, McCarthy E, Niculete M, Santoro G, Hermes E. Does format matter? A naturalistic study of digital and provider-led cognitive behavioral therapy for insomnia implemented in a healthcare system. Behavioral Sleep Medicine 2024, 22: 883-893. PMID: 39140646, DOI: 10.1080/15402002.2024.2385822.Peer-Reviewed Original ResearchCognitive Behavioral Therapy for InsomniaVeterans Health AdministrationHealthcare settingsLevels of program engagementSelf-directed careEvidence-based treatmentsCognitive behavioral therapyProgram engagementHealth AdministrationProgram increased accessHealthcare systemTreatment engagementCoaching supportHealthcareBehavioral therapyInsomnia severityProvidersSymptom changeInsomniaClinical effectsInsomnia disorderSimilar outcomesImpairing disorderNaturalistic studyIndividualsAAPM Task Group Report 267: A joint AAPM GEC‐ESTRO report on biophysical models and tools for the planning and evaluation of brachytherapy
Chen Z, Li X, Brenner D, Hellebust T, Hoskin P, Joiner M, Kirisits C, Nath R, Rivard M, Thomadsen B, Zaider M. AAPM Task Group Report 267: A joint AAPM GEC‐ESTRO report on biophysical models and tools for the planning and evaluation of brachytherapy. Medical Physics 2024, 51: 3850-3923. PMID: 38721942, DOI: 10.1002/mp.17062.Peer-Reviewed Original ResearchDose delivery patternClinical medical physicistsBrachytherapy modalitiesMedical physicistsAAPM Task Group ReportAmerican Association of PhysicsBrachytherapy treatment planningTask group reportRadioactive sourcesDevelopment of biophysical modelsEuropean Society for Radiotherapy & OncologyGEC-ESTRORadiobiological effectsAAPMRadiation oncologyBrachytherapyBiophysical modelTreatment planningPhysicistsClinical effectsClinical backgroundIrradiated tissueDelivery patternsPractice guidelinesTreatment techniquesCorrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 15: 1372373. PMID: 38435972, PMCID: PMC10905264, DOI: 10.3389/fpsyt.2024.1372373.Peer-Reviewed Original ResearchSafety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D’Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 14: 1278823. PMID: 38264632, PMCID: PMC10803438, DOI: 10.3389/fpsyt.2023.1278823.Peer-Reviewed Original ResearchObsessive-compulsive disorderPrimary outcomeNon-directive supportClinical effectsTreatment-refractory obsessive-compulsive disorderRefractory obsessive-compulsive disorderSingle-dose trialBlinded ratingsWaitlist-controlled trialDose selection strategiesOCD symptom reductionTreatment of OCDEffects of psilocybinSingle-site trialOCD symptomsInstitutional review boardBlinded independent ratersTrials of psilocybinYale-Brown ObsessiveWaitlist control designPrimary endpointMore dosesFuture trialsSingle dosePsilocybin treatmentKnowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms
McCulloch D, Lopez J, Dalla C, Castrén E, Erritzoe D, Frokjaer V, Lundberg J, Preller K, Fisher P, Knudsen G. Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms. Neuroscience Applied 2024, 3: 103929. DOI: 10.1016/j.nsa.2023.103929.Peer-Reviewed Original ResearchSerotonin 2A receptorFunctional brain activityMechanism of actionClinical effectsPreclinical modelsBrain disordersClinical neuroimagingDose optimizationNeurotransmitter releaseEffects of psychedelicsBrain activitySex differencesPsychedelic drugsMolecular mechanismsKnowledge gapsPsychedelicsAppropriate behavioral modelsPreclinicalNeuroimagingReceptorsEfficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Efficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF. Journal Of Cardiac Failure 2024, 30: 312-313. DOI: 10.1016/j.cardfail.2023.10.467.Peer-Reviewed Original ResearchSacubitril/valsartanPIONEER-HFHeart failurePooled analysisNT-proBNPControl therapyDe novo heart failurePlasma NT-proBNP levelsIndependent clinical events committeeIndividual patient-level analysisNovo heart failureNT-proBNP levelsClinical events committeePatient-level analysisCardiovascular deathHemodynamic stabilizationPrimary endpointSymptomatic hypotensionRenal functionMedian ageClinical outcomesRandomized trialsClinical effectsEvents committeeHF events
2023
Clinical experience with the use of inhaled isopropyl alcohol to treat nausea and vomiting: A narrative review.
Amaya S, Kalsotra S, Tobias J, Olbrecht V. Clinical experience with the use of inhaled isopropyl alcohol to treat nausea and vomiting: A narrative review. Saudi Journal Of Anaesthesia 2023, 17: 383-390. PMID: 37601520, PMCID: PMC10435785, DOI: 10.4103/sja.sja_151_23.Peer-Reviewed Original ResearchInhaled isopropyl alcoholNausea and vomitingTreatment of PONVPerioperative settingAntiemetic agentsOperating roomManagement of nausea and vomitingTreat nausea and vomitingTreatment of postoperative nauseaRisk of adverse effectsLow risk of adverse effectsSeverity of PONVShort-term treatmentNarrative reviewAdverse effectsEmergency department settingAction of IAMechanism of actionAdult patientsTreat PONVAntiemetic effectPostoperative nauseaClinical trialsClinical effectsInexpensive therapyHealth Disparities in Peripheral Artery Disease: A Scientific Statement From the American Heart Association
Allison M, Armstrong D, Goodney P, Hamburg N, Kirksey L, Lancaster K, Mena-Hurtado C, Misra S, Treat-Jacobson D, Solaru K, Health O. Health Disparities in Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation 2023, 148: 286-296. PMID: 37317860, PMCID: PMC11520198, DOI: 10.1161/cir.0000000000001153.Peer-Reviewed Original ResearchConceptsPeripheral artery diseaseArtery diseaseClinical effectsAmerican Heart AssociationMajor limb amputationCerebrovascular eventsHeart AssociationHigh prevalenceLimb amputationHealth disparitiesInequitable deliveryInequitable burdenScientific statementHigh rateCertain demographic groupsDiseasePotential novel solutionIndividual disabilityOverview statementDemographic groupsAmputationDisparitiesPrevalenceCareStructural inequities
2022
Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA
Kauke-Navarro M, Knoedler S, Panayi AC, Knoedler L, Noel OF, Pomahac B. Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA. Transplantation 2022, 107: 86-97. PMID: 36210500, DOI: 10.1097/tp.0000000000004342.Peer-Reviewed Original ResearchConceptsSolid organ transplantationOrgan transplantationSide effectsField of VCAMedication side effectsBeneficial clinical effectsChimeric antigen receptorSevere side effectsRisk of infectionT cell receptorMaintenance immunosupressionMetabolic complicationsClinical effectsTransplant rejectionLifelong immunosuppressionImmune cellsTregsComposite allotransplantationSpecific antigenTherapeutic efficacyAntigen receptorStable levelPrecision medicineImmune system mechanismsImmunotoleranceManagement of Phenibut Use Disorder and Withdrawal in a Geriatric Patient
Wainblat E, Weleff J, Anand A. Management of Phenibut Use Disorder and Withdrawal in a Geriatric Patient. American Journal Of Geriatric Psychiatry 2022, 31: 67-74. PMID: 36266201, DOI: 10.1016/j.jagp.2022.09.008.Peer-Reviewed Original ResearchConceptsUse disorderAlcohol use disorderAnxiolytic use disorderWorsen affective disordersAffective disordersPhysiological dependenceMisuse substancesNootropic propertiesWithdrawal managementAlleviate anxietyFood and Drug AdministrationDisordersPhenibutWithdrawalAddictionClinical effectsGeriatric patientsDrug AdministrationGeriatric populationDrug profileAlcoholAnxietyBenzodiazepinesAnxiolysisInsomniaEffect of the STRIDE fall injury prevention intervention on falls, fall injuries, and health‐related quality of life
Ganz DA, Yuan AH, Greene EJ, Latham NK, Araujo K, Siu AL, Magaziner J, Gurwitz JH, Wu AW, Alexander NB, Wallace RB, Greenspan SL, Rich J, Volpi E, Waring SC, Dykes PC, Ko F, Resnick NM, McMahon SK, Basaria S, Wang R, Lu C, Esserman D, Dziura J, Miller ME, Travison TG, Peduzzi P, Bhasin S, Reuben DB, Gill TM. Effect of the STRIDE fall injury prevention intervention on falls, fall injuries, and health‐related quality of life. Journal Of The American Geriatrics Society 2022, 70: 3221-3229. PMID: 35932279, PMCID: PMC9669115, DOI: 10.1111/jgs.17964.Peer-Reviewed Original ResearchConceptsHealth-related qualityHospital admissionEQ-5DMedical attentionLeast square mean changeFall injury riskSelf-reported fracturesFall-related fracturesFall-related outcomesIncidence rate ratiosInjury prevention interventionsPrimary care practicesReal-world effectivenessFall prevention studiesMeaningful clinical effectsGOV IDENTIFIERUsual careMultifactorial interventionClinical effectsEQ-VASPrevention StudyFall injuriesOlder adults ageMean changePrevention interventions
2021
Effect of Mahuang Fuzi and Shenzhuo Decoction on Idiopathic Membranous Nephropathy: A Multicenter, Nonrandomized, Single-Arm Clinical Trial
Dong Z, Dai H, Gao Y, Jiang H, Liu M, Liu F, Liu W, Feng Z, Zhang X, Ren A, Li X, Rui H, Tian X, Li G, Liu B. Effect of Mahuang Fuzi and Shenzhuo Decoction on Idiopathic Membranous Nephropathy: A Multicenter, Nonrandomized, Single-Arm Clinical Trial. Frontiers In Pharmacology 2021, 12: 724744. PMID: 34733157, PMCID: PMC8558382, DOI: 10.3389/fphar.2021.724744.Peer-Reviewed Original ResearchIdiopathic membranous nephropathySingle-arm clinical trialMahuang-FuziMembranous nephropathyCourse of treatmentRemission rateImmunosuppressive therapyDisease remissionUrine proteinClinical trialsSevere adverse eventsCases of patientsMean followAdverse eventsRenal functionClinical effectsNephropathyPatientsBlood albuminRemissionTherapyDecoctionMulticenterObjective performance criteriaTreatmentLow-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement
Lee H, Blumberger D, Lenze E, Anderson S, Barch D, Black K, Cristancho P, Daskalakis Z, Eisenstein S, Huang Y, Li S, Lissemore J, McConathy J, Mulsant B, Rajji T, Reynolds C, Su Y, Tu Z, Voineskos D, Karp J. Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement. Biological Psychiatry Global Open Science 2021, 2: 127-135. PMID: 36325158, PMCID: PMC9616305, DOI: 10.1016/j.bpsgos.2021.09.003.Peer-Reviewed Original ResearchTranscranial magnetic stimulation measuresTreatment-resistant depressionPositron emission tomographyFunctional magnetic resonanceTarget engagementClinical trialsCortical transmissionMontgomery-Åsberg Depression Rating ScalePlacebo-controlled clinical trialEmission tomographyLow-dose augmentationVenlafaxine extended releasePrimary outcome measureBlood oxygen level-dependent (BOLD) responseMajor depressive episodeDepression Rating ScaleExperimental therapeutic approachesYears of ageMultimodal assessmentLevel-dependent responsesMonetary incentive delay taskBrain positron emission tomographyPlacebo groupIncentive delay taskClinical effects
2020
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza D. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2020, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.Peer-Reviewed Original ResearchConceptsTherapeutic effectAdverse eventsSingle administrationPsychotropic effectsWeekly migraine daysSerious adverse eventsCross-over studyEffects of psilocybinOral placeboMigraine daysMigraine frequencyClinical effectsControlled StudyHeadache disordersMigraine headacheHeadache diaryDrug effectsDrug AdministrationNeuropsychiatric conditionsMigraineFinal analysisStudy proceduresReceptor ligandsWeeksAdministrationCross-frequency coupling between gamma oscillations and deep brain stimulation frequency in Parkinson’s disease
Muthuraman M, Bange M, Koirala N, Ciolac D, Pintea B, Glaser M, Tinkhauser G, Brown P, Deuschl G, Groppa S. Cross-frequency coupling between gamma oscillations and deep brain stimulation frequency in Parkinson’s disease. Brain 2020, 143: 3393-3407. PMID: 33150359, PMCID: PMC7116448, DOI: 10.1093/brain/awaa297.Peer-Reviewed Original ResearchConceptsDeep brain stimulationBrain stimulationParkinson's diseaseStimulation frequencyCross-frequency couplingMotor symptomsSubthalamic nucleusGamma oscillationsDeep Brain Stimulation FrequencyOscillatory activityPhysiological neural activityMotor function recoveryEffective deep brain stimulationHigh-frequency stimulationPathological oscillatory activityCross-frequency interactionsCortico-subcortical networksDifferent oscillatory activitiesSymptom controlParietal cortex regionsClinical effectsFunction recoverySymptom alleviationMotor impairmentSubcortical regions
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply